Ikena Oncology Inc (NAS:IKNA)
$ 1.735 -0.115 (-6.22%) Market Cap: 83.73 Mil Enterprise Value: -47.05 Mil PE Ratio: 0 PB Ratio: 0.59 GF Score: 30/100

Ikena Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 25, 2023 / 06:30PM GMT
Release Date Price: $4.9 (-1.01%)
Stephen Willey
Stifel Nicolaus & Co., Inc. - Analyst

All right. Thanks, everyone. I'm Stephen Willey, one of the senior analysts here at Stifel, and glad to have with us presenting from Ikena Oncology, CEO, Mark Manfredi. He's going to be giving us a presentation. If there's some time left for Q&A, we'll get into it. I think there's a chat function as well that can be used to populate any investor questions that you may have. So Mark, I'm going to turn it over to you, and really appreciate the participation today. Thank you.

Mark Manfredi
Ikena Oncology, Inc. - President & CEO

Thanks, Stephen, and thanks for the invitation to talk about the company. And so I'm going to start just a little bit of an overview of us. So Ikena Oncology. We're focused on targeted oncology, clinical assets in the pipeline. And we're really on two pathways. One is the Hippo pathway, which I'll spend most of the time today, which is a first-in-class opportunity to target a transcription factor called TEAD. And in the second is a well-known pathway called the RAS pathway

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot